COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,093 Articles (22,658 medRxiv, 8,435 bioRxiv)

Most recent first Previous |  Page 1497: Articles 14961-14970  | Next

Detection of SARS-CoV-2 in saliva using tailed amplicon sequencing
Garoutte, A., Santiago-Rodriguez, T. M., Fehling, H. L., Iwasiow, R.
10.1101/2021.05.19.21257217 — Posted: 2021-05-21
Characterization of the Second Wave of the COVID-19 Pandemic in India: A Google Trends Analysis
Visaria, A., Polamarasetti, P., Reddy, S., Ali, A., Hameed, F. R., James, J., Akhtar, M., Islam, S., Raju, P., Thawani, R.
10.1101/2021.05.19.21257473 — Posted: 2021-05-21
Topic: Hyper immune Bovine Colostrum as a Low-Cost, Large-Scale Source of Antibodies against COVID-19
Nili, H., Bouzari, M., Attaran, H. R., Golab, N. G., Rabani, M.
10.1101/2021.05.20.444932 — Posted: 2021-05-20
Fluorescence signatures of SARS CoV-2 spike S1 proteins and an human ACE-2: excitation-emission maps and fluorescence lifetimes
Grzesiak, J., Fellner, L., Grünewald, K., Kölbl, C., Walter, A., Horlacher, R., Duschek, F.
10.1101/2021.05.20.444935 — Posted: 2021-05-20
A COVID-19 Community Vulnerability Index to drive precision policy in the US
Smittenaar, P., Stewart, N., Sutermaster, S., Coome, L., Dibner-Dunlap, A., Jain, M., Caplan, Y., Campigotto, C., Sgaier, S. K.
10.1101/2021.05.19.21257455 — Posted: 2021-05-20
Differential interferon-α subtype immune signatures suppress SARS-CoV-2 infection
Schuhenn, J., Meister, T. L., Todt, D., Bracht, T., Schork, K., Billaud, J.-N., Elsner, C., Heinen, N., Karakoese, Z., Haid, S., Kumar, S., Brunotte, L., Eisenacher, M., Chen, J., Yuan, Z., Pietschmann, T., Wiegmann, B., Beckert, H., Taube, C., Le-Trilling, V. T. K., Trilling, M., Krawczyk, A., Ludwig, S., Sitek, B., Steinmann, E., Dittmer, U., Sutter, K., Pfaender, S.
10.1101/2021.05.20.444757 — Posted: 2021-05-20
A CRISPR/Cas9 genetically engineered organoid biobank reveals essential host factors for coronaviruses
Beumer, J., Geurts, M. H., Lamers, M. M., Puschhof, J., Zhang, J., van der Vaart, J., Mykytyn, A. Z., Breugem, T. I., Riesebosch, S., Schipper, D., van den Doel, P. B., de Lau, W., Pleguezuelos-Manzano, C., Busslinger, G., Haagmans, B. L., Clevers, H.
10.1101/2021.05.20.444952 — Posted: 2021-05-20
4'-Fluorouridine is a broad-spectrum orally efficacious antiviral blocking respiratory syncytial virus and SARS-CoV-2 replication
Sourimant, J., Lieber, C., Aggarwal, M., Cox, R., Wolf, J., Yoon, J.-J., Toots, M., Ye, C., Sticher, Z., Kolykhalov, A. A., Martinez-Sobrido, L., Bluemling, G. R., Natchus, M. G., Painter, G. R., Plemper, R. K.
10.1101/2021.05.19.444875 — Posted: 2021-05-20
Acute SARS-CoV-2 infection is associated with an expansion of bacteria pathogens in the nose including Pseudomonas aeruginosa
Rhoades, N. S., Pinski, A., Monsibais, A. N., Jankeel, A., Doratt, B. M., Cinco, I. R., Ibraim, I., Messaoudi, I.
10.1101/2021.05.20.445008 — Posted: 2021-05-20
An AAV-ie based Vaccine effectively protects against SARS-CoV-2 and Circulating Variants
Zhao, S., Tan, F., Ke, J., Yang, J., Lin, C.-b., Wang, H., zhong, g.
10.1101/2021.05.19.444889 — Posted: 2021-05-20

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).